Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018 | ||
By: Nasdaq / GlobeNewswire - 18 Oct 2018 | Back to overview list |
|
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will release its third quarter 2018 financial results on Wednesday October 24, 2018 and will host a webcasted conference call at 4:30 p.m. Eastern Time. Conference Call at 4:30 p.m. Eastern Time on October 24, 2018 About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II), formerly known as LJPC-501, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. LJPC?401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. For more information, please visit www.ljpc.com. Company Contacts Sandra Vedrick and Dennis M. Mulroy Media Contact Sylvia Wheeler |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |